Recombinant immunotoxins (RIT) are targeted anti-cancer agents that are composed of a targeting antibody fragment and a protein toxin fragment. SS1P is a RIT that targets mesothelin on the surface of cancer cells and is being evaluated in patients with mesothelioma. Mesothelin, like many other target antigens, is shed from the cell surface.
Quick Guide to Equations and Assumptions

Tumor volume and cell composition changes
The tumor volume is obtained from the flux of cells across the outer boundary, r o , of RU using:
where V is the tumor volume, u(r o ) is the velocity of the cell flow at r o , and The density of normal tumor cells in EVS, ρ 1 , is governed by:
where
and ī and f are the rate constants of the cell growth and the intoxication, respectively.
The first term in eq. (B') represents the change in the cell density at any given point due to the cells flowing into and out of the given point. The second term in eq. (B') represents the change in the cell density (generally, any quantity x) due to the material that flows in or out of RU.
Similar expressions govern the densities of the other two cell types, the intoxicated and the dead cells. The cell flow velocity u(r,t) is determined from the condition that the sum of these three densities, ρ * = ρ 1 + ρ 2 + ρ 3 , is constant over r or t.
The intoxication rate and the toxin concentrations inside the cell
The intoxication rate constant f (r,t) in equation (B) measures the rate of conversion of type 1 to type 2 cells. It is assumed to depend linearly on the toxin concentration in the cytosol of type 1 cells and, therefore, couples the set of equations that govern the cell densities and the set of equations that govern the toxin concentrations. The toxin concentrations in the cytosol and in all other compartments within the cell, which we refer to generically as 'endosome', are given by the following coupled equations: Author Manuscript Published OnlineFirst on May 4, 2012; DOI: 10.1158/0008-5472. endosome into the cytosol, endocytosis, toxin inactivation in the cytosol, and toxin inactivation in the endosome, respectively. Similar equations govern the toxin concentrations in type 2 and 3 cells, except that the endosome and cytosol are combined for the type 3 cells.
Receptor turnover and shedding
The RIT enters cells when the RIT-receptor complex on the cell surface enters cells through endocytosis. The receptors are removed from the surface by endocytosis and by shedding into the ECS and replenished by migration to the surface from the interior of the cell. (See the Supplemental Figure S2 .) The total number of receptors (free plus RITcomplexed) on the surface of each cell is governed by the following coupled equations:
where tR i CS and tR i C are the total number of receptors per cell on the surface and in the interior of cell type i, k s , k c , and k deg are the rate constants for shedding, recycling (migration from inside to the surface), and degradation of receptors, respectively, Q 1 is the protein synthesis rate in cell type 1 and Q 2 = 0 . The number of RIT-receptor complexes is obtained from the total number of receptors and the free RIT concentration in the ECS using the RIT-receptor on and off reaction rates.
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The RIT concentration in the extracellular space (ECS)
The mass balance equation for the concentration of free (uncomplexed) RIT, T , in ECS
where D and χ ecs are the diffusion and the degradation rate constants of free RIT in 
INTRODUCTION
Many anti-cancer agents are composed of antibodies attached to cytotoxic drugs or protein toxins (1, 2) . They bind to the specific target antigen on the surface of cancer cells and then are internalized and processed to release the cytotoxic component within the target cell. Generally, they work better on leukemias than against solid tumors, because of factors in solid tumors that are known to limit the entry and dispersal of these agents.
The physical process of the delivery of the antigen-targeting agents through the solid tumor tissue has been the subject of numerous studies and several reviews are available(3-7).
It is well known that many tumor-specific surface antigens, including CA125, Her-2/neu, PSA, CEA, and others, are actively shed from cancer cells (8) . Such shedding can be expected to significantly influence the delivery of anti-cancer agents that use these antigens as the delivery target (9) . However, no theoretical study has been reported on the effect of antigen shedding on the delivery of these agents in solid tumors.
We previously reported on a mathematical model that relates the tumor volume changes to the dose level of the administered recombinant immunotoxins (RITs) (10) . RITs are targeted anti-cancer agents and composed of a targeting antibody fragment and a protein toxin fragment. The model takes into account various physical events that the RIT encounters during its travel from the blood vessel to the cytosol of a tumor cell. The original model(10) employed mass balance equations for two types of tumor cells, the normal and the intoxicated, using fluid like treatment of cells (11, 12 mice, which had been given different doses of RIT, and demonstrated the well-known binding site barrier effect (13, 14) . It also identified nearly 20 factors that were involved in the RIT trafficking process, some of which were predicted to affect the RIT-induced tumor volume change much more than others.
For the current study, we modified this original model in several different ways (see Methods), one of which was to include the effect of target antigen shedding. We apply this modified model to the specific case of SS1P (anti-mesothelin-Fv-PE38), which is one of the most extensively studied RITs. SS1P binds to mesothelin expressed on cells of several different types of solid tumors including mesothelioma, ovarian cancer, pancreatic cancer and lung cancer (15) . Currently SS1P is being evaluated for the treatment of mesothelioma (16) (17) (18) .
We have shown that mesothelin is actively shed in large quantities into the extracellular space (ECS) of the tumor and into the blood (19) . In the case of the mesothelin-expressing A431 tumors, we expect the shedding rate constant to be approximately 0.4 per hour (see the Methods section), which is roughly comparable to the endocytosis rate of approximately 0.22 per hour that we estimate from the data of Zhang et al. (20) . The surface mesothelin lost through shedding and endocytosis is replenished in normal tumor cells by fresh protein synthesis.
It seemed possible that the shed free mesothelin could act as a decoy in the ECS of the solid tumor, thereby reducing the free RIT concentration available for binding to the cell surface antigen. Also, the RIT bound to mesothelin on the cell surface can be released back to the ECS instead of entering the cell by endocytosis when the mesothelin is shed from the surface. Indeed, we have shown that addition of an inhibitor to the mesothelin sheddase in cell cultures reduced shedding and increased the concentration of SS1P inside the cells (19) . Because of these effects, antigen shedding was expected to reduce targeting efficiency (21) . Surprisingly, the model shows that antigen shedding greatly enhances, not retards, the effectiveness of the RIT in the solid tumor. The reason is, in part, that the shed antigen acts as a protective reservoir of RIT, which helps to bypass the binding site barrier (22) . This finding has important implications in designing methods for an efficient delivery of this class of anti-cancer agents against solid tumors.
METHODS
The model setup
The model treats a tumor as a collection of identical representative units (RUs, Figure 1 (20) . Future models will include these other cell types. Each cell has three compartments -the surface, the cytosol, and the remainder, which we designate generically as endosome -except that we combine cytosol and endosome for the dead cells.
The mathematical model consists of two main sets of differential equations. One set describes the kinetic steps that the RIT molecules go through within the RU from 
Model parameters
The parameter values that were used for the model reported herein are given in the Supplemental Table S1 . They are either taken from the earlier work (10) 
RESULTS
The model gives a good fit with the experimental dose-response data
The model integrates the preclinical testing data of SS1P, most of which come from experiments in which SS1P was injected i.v. to treat mesothelin-expressing A431 tumors engrafted into nude mice. To be consistent with the clinical practice, SS1P was given every other day for a total of 3 doses. The change of tumor volume after treatment was tracked. decreases after each injection as it is degraded (blue curve). The sum of the active and degraded RIT (purple curve) equals the total amount of RIT that crossed the blood vessel wall to enter the ECS of the tumor tissue up to each time point. Thus, the current model fully accounts for all the RIT that entered the EVS of the tumor tissue at all times. This precision is a significant improvement over the previous model(10).
The total amounts that crossed the blood vessel to enter the tumor EVS are 0.4% to 0.6% of the total injected dose ( Table 1) -3925 injection is similar, except that the total amount degraded is larger since the RIT from injections 2 and 4 days before has been degraded. By one day after the last injection, 98% of the RIT has been degraded, most of which (78%) within type 1 cells. Thus, the tumor cells are the major sink of RIT.
Antigen shedding improves efficacy of RIT
Unless otherwise stated, our model assumes that antigen is shed. We obtain the nonshedding model by setting the shedding rate to zero and by correspondingly reducing the receptor synthesis and recycling rates so as to maintain the same number of antigen molecules on the cell surface as when the antigen is shed (See Supplemental Materials and Methods and Figure S2 ). When the shedding is maintained at the same rate, but the dissociation rate of the shed antigen-RIT complex is set to zero, the tumor keeps growing without shrinkage (red curve, 'shedding without RIT release'). In this case, the shed antigen does act as a sink and efficiently reduces the amount of RIT available to bind the surface antigen, a necessary step before the RIT can kill the cell. 
What is striking is the result for the non-shedding case in which there is no antigen in the ECS to serve as a sink. Quite unexpectedly, the RIT treatment in this case (broken blue curve) has a much diminished anti-tumor effect compared to the shedding case (solid blue curve) and only slightly better than when the shed antigen acts as a sink (red curve). The number of cells killed in the non-shedding case is less than that in the shedding case at half the dose (data not shown). Thus, the model indicates unambiguously that antigen shedding makes the RIT substantially more effective. volume. These data suggest that shed antigen helps carry the RIT away from the blood vessel and circumvent the binding site barrier.
The radial distribution of the concentration of free RIT in ECS directly shows this to be the case. Indeed, Figure 5b shows that the free RIT concentration decreases sharply beyond about 20 ȝm in the non-shedding case (right panel) but is maintained, albeit at a low level, in the shedding case (left panel).
In contrast, the concentration of the shed antigen-RIT complexes in ECS displays virtually no radial distance dependence after initial first hour of the last (3 rd ) injection (Supplemental Figure S3 ). This is because the complexed RIT does not bind the surface antigen and because the diffusion of these molecules, although slower than the smaller RIT molecules, is still fast enough for them to permeate the entire volume of the tumor tissue in a few hours. In effect, the shed antigen serves as a carrier of RIT, protecting it from excessively binding to the surface antigen during its transport to the distant parts of the tumor tissue. Wherever they are transported, these RIT-antigen complexes release RIT continually at a low level, in a dynamic association-dissociation equilibrium process, making them available to bind the surface antigen.
Antigen shedding causes favorable RIT distribution among tumor cells
There is another mechanism by which the antigen shedding enhances RIT efficacy. 
DISCUSSION
The model presented here is based on the model we described earlier(10), but we improved it by re-writing the entire set of differential equations to make the model quantitatively more precise, to recognize three rather than two cell types, and most importantly by including the effect of antigen shedding, which was not included in the original model. (27) .) The total number of RIT molecules in a yet-to-be-intoxicated tumor cell is less than 1000 molecules (Figure 6a) , which is consistent with the experimental finding of Kreitman & Pastan(23) .
The main finding of this study is that antigen shedding enhances the efficacy of RIT, contrary to the suggestion some of us made earlier (see below). Shedding improves the RIT efficacy in two ways. One mechanism is through circumventing the binding site barrier (13, 28) , which is recognized as one of the main reasons for the non-homogeneous (29)). When sinks are present, the penetration can be delayed by days or, in principle, forever. Here we found that antigen shedding is an effective natural way of circumventing this barrier. The shed antigen acts as a protective reservoir, which carries RIT into spaces far removed from the blood vessel without excessive binding to the surface antigens in transit and which preserves it for a long time after the last injection. This is consistent with the expectation that a non-binder, as the shed antigen-RIT complex is, will spread throughout the tumor tissue in hours (4) or less (14) . Secondly, shedding reduces wasteful binding of RIT to the already intoxicated cells by reducing the surface antigen concentration on these cells. Indeed, we have observed experimentally that incubation of cells with RIT can reduce cell surface mesothelin by 90% within 3 hours (unpublished data). This reduction must be due to the fact that RIT induces protein synthesis inhibition and the surface mesothelin is no longer replenished while it is being lost by shedding as well as by endocytosis.
There is strong experimental evidence that indicates that a RIT reservoir exists in the tumor tissue. Previously, we intravenously injected dye-labeled mutant SS1P into mice bearing mesothelin-expressing tumors (20) . The mutation (E553D) inactivates the toxin part of the molecule so that it does not kill cells. We found that the peak of intra-cellular staining appeared 6 hours after SS1P was cleared from the blood ( Figure 3A in Zhang et al. (20) ). This delay suggests that there is a reservoir in the tumor that supplies SS1P long Some of us observed that mesothelin was shed in the human tumor growing in mice and that administration of taxol, which exerts synergistic effect with SS1P, reduced the concentration of shed mesothelin. From this observation, we surmised that the synergy was due to the reduction of shed antigen concentration and that shed antigen must hinder the action of SS1P (20, 21, 30) . However, the synergistic effect of taxol can arise from a different mechanism (see below), independent of the reduction in the shed antigen concentration. More recently, some of us showed that reducing shedding significantly improved the cytotoxicity of immunotoxin SS1P (19) . However, this is an observation made on an in vitro cell culture system, in which the beneficial effect of shed antigen acting as a protective carrier and reservoir of RIT is not expected to exist as it does in a solid tumor.
Some suggestions on improving the potency of RITs as anti-cancer agent can be made based on the results that this model produced. For example, the benefit of antigen shedding should be considered in selecting potential targets. One could also consider using the antigen or antigen analogs in combination to serve as the carrier and protective reservoir of the RIT. Adding competing (non-toxic) antibody in judicious amounts can also help as it would increase the concentration of RIT in the reservoir. 
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